Seres Therapeutics Inc (MCRB)

Jan 16, 2025, 7:00 AM EST - 1 day ago

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

Jan 9, 2025, 7:00 AM EST - 8 days ago

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

Dec 16, 2024, 7:00 AM EST - 4 weeks ago

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

Nov 22, 2024, 7:00 AM EST - 2 months ago

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

Nov 13, 2024, 10:28 AM EST - 2 months ago

Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 7:00 AM EST - 2 months ago

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

Sep 30, 2024, 5:15 PM EDT - 3 months ago

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

Sep 27, 2024, 3:26 PM EDT - 4 months ago

Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé

Sep 26, 2024, 4:01 PM EDT - 4 months ago

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

Sep 23, 2024, 12:14 AM EDT - 4 months ago

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Sep 13, 2024, 7:00 AM EDT - 4 months ago

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

Sep 12, 2024, 7:00 AM EDT - 4 months ago

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Aug 13, 2024, 3:35 PM EDT - 5 months ago

Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:00 AM EDT - 5 months ago

Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024

Aug 6, 2024, 7:00 AM EDT - 5 months ago

Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science

Jun 7, 2024, 4:00 PM EDT - 8 months ago

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 6, 2024, 7:00 AM EDT - 8 months ago

Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023

Jun 6, 2024, 6:30 AM EDT - 8 months ago

Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science

May 11, 2024, 5:34 PM EDT - 8 months ago

Seres Therapeutics, Inc. (MCRB) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:00 AM EDT - 9 months ago

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 6, 2024, 9:30 AM EDT - 9 months ago

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024

Apr 9, 2024, 7:00 AM EDT - 10 months ago

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Apr 2, 2024, 2:10 AM EDT - 10 months ago

VKTX, JANX and these biotech stocks are surging in 2024

ARQT JANX VKTX AMLX RAPT RVNC

Mar 5, 2024, 3:33 PM EST - 11 months ago

Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 7:00 AM EST - 11 months ago

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Feb 28, 2024, 7:00 AM EST - 11 months ago

Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024

Feb 27, 2024, 7:00 AM EST - 11 months ago

Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference

Feb 26, 2024, 7:00 AM EST - 11 months ago

Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz

Jan 9, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

Jan 4, 2024, 4:00 PM EST - 1 year ago

Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 7, 2023, 7:46 PM EST - 1 year ago

Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023

Nov 28, 2023, 9:18 AM EST - 1 year ago

Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET

Nov 4, 2023, 11:52 AM EDT - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 7:00 AM EDT - 1 year ago

Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million

Oct 30, 2023, 5:30 PM EDT - 1 year ago

Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST

Oct 12, 2023, 7:00 AM EDT - 1 year ago

Seres Therapeutics to Highlight VOWST™ Data at IDWeek

Sep 11, 2023, 6:30 AM EDT - 1 year ago

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

DNLI FHTX MRNA OMGA SANA

Sep 7, 2023, 10:00 AM EDT - 1 year ago

Seres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 1, 2023, 2:03 PM EDT - 1 year ago

Seres Therapeutics: Approved Drug And Nestle Partnership Make It A Buy

Aug 8, 2023, 3:03 PM EDT - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 7:00 AM EDT - 1 year ago

Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

Aug 3, 2023, 3:37 PM EDT - 1 year ago

Seres Therapeutics: VOWST's Time To Shine

Aug 1, 2023, 7:00 AM EDT - 1 year ago

Seres Therapeutics to Host Second Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on August 8, 2023

Aug 1, 2023, 7:00 AM EDT - 1 year ago

Seres Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference

Jun 21, 2023, 9:00 AM EDT - 1 year ago

Seres Therapeutics Named to TIME100 Most Influential Companies List

Jun 21, 2023, 6:00 AM EDT - 1 year ago

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

DNLI FHTX MRNA OMGA SANA

Jun 17, 2023, 3:45 PM EDT - 1 year ago

Seres Therapeutics and Nestlé Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023

Jun 9, 2023, 7:00 AM EDT - 1 year ago

Seres Therapeutics to Present at Goldman Sachs Global Healthcare Conference

Jun 5, 2023, 7:00 AM EDT - 1 year ago

Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection